►
From YouTube: Open Source Antibiotics Science Update Oct 23 2020
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/36
On the call: Professor Matthew Todd, Dr Edwin Tse, Giada Sabatino, Yuhang Wang (all University College London), Dr Chris Swain (Cambridge MedChem Consulting), Anthony Sama, Alvaro Lorente (University of Edinburgh)
A
A
Okay,
so
hopefully
you
can
see
the
the
draft
here.
So
the
idea
behind
this
meeting
was
to
talk
about
the
the
new
data
that
we
are
about
to
get
from
screening
a
bunch
of
molecules,
both
synthesized
in-house
and
donated
from
various
sources
via
ben
perry,
and
that
screen
is
happening
right
now,
so
we
don't
quite
have
the
data
yet
so
this
meeting
will
be
short.
A
I
think,
because
we're
of
course
waiting
on
that
the
most
important
thing
we're
waiting
for
is
so
here
are
the
it's
going
to
be
quite
small
as
now
here
are
the
things
being
evaluated
and
let
me
just
try
and
make
that
bigger.
I
don't
see
you
making
that
bigger.
That's
no
good!
I
think
I'm
making
everything
bigger,
except
the
picture,
hang
on
a
second
there.
You
go
that's
better.
A
So
the
main
thing
really
for
for
this
is
that
we
are
trying
to
see
if
the
donated
compounds
which
has
this
fused
pyridine
core
are
active
because
a
bunch
of
molecules
are
donated
with
that.
That's
a
key
thing,
and
so
that's
gonna.
You
know
help
answer
that
question
as
well
as
a
bunch
of
other
changes
that
we've
made.
Specifically
these
compounds
he1861862
with
the
isomers
of
the
pyridine.
A
Unfortunately,
so
that's
our
main
thing,
but
also
all
the
compounds
are
there
and
it's
a
really
nice
set
of
compounds
which
is
good,
okay
and,
of
course,
as
soon
as
we
get
that
we'll
post
it,
but
we
just
have
to
wait
for
them
to
come
in
eddie.
Do
you
want
to
just
talk
about
some
chemistry
this
week
is
now
a
good
time,
yeah.
B
B
So
yeah
nothing
really
too
new.
So
I'm
just
going
to
reuse
some
of
the
old
slides.
So
this
compound
with
the
pyrazine.
So
I
did
the
suzuki
of
that
yesterday.
I
just
need
to
purify
that
the
pyrimidine
I've
made
the
brominated
core.
So
I
need
to
do
the
suzuki
on
that
and
then
so.
This
compound,
which
I
didn't
include
in
this
batch.
So
I
had
a
similar
problem
to
what
dana
had
with
the
benzo
furan
with
this
core,
where
she
was
getting
triphenylphosphine
oxide
that
she
couldn't
separate
out.
B
B
A
B
A
A
A
We
were
just
talking
about
the
the
screen
that
was
happening
yeah.
Let
me
very
very
briefly
just
show
you
that,
because
it's
on
one
of
the
issues,
that's
linked
in
the
agenda,
but
it's
it's
a
a
bunch
of
combats
being
evaluated
right
now
with
some
of
these
cores
that
were
donated
through
ben
perry's,
open
synthesis
network
and
other
things.
A
People
send
us
a
mail
if
they
want
to
sign
up
for
it.
I
haven't
in
the
past,
we've
been
quite
corporate
about
it
and
had
email
addresses
that
are
based
on
the
project
itself.
So
we've
got,
you
know,
sort
of
open
source,
malaria,
gmail.com
and
all
that
kind
of
thing.
We
haven't
done
that
with
this
project.
Yet
so
we
haven't
got
a
sort
of
corporate
open
source
antibiotics
email
address,
because
it's
a
questionable
usefulness,
so
I've
just
sort
of
sent
it
from
me
and
future
newsletters
can
come
from
anybody.
A
If
we,
you
know,
write
them
online
together
and
send
them
out.
It
means
if
someone
wants
to
sign
up.
You
know
we
don't
have
an
automated
way
of
doing
that,
so
we
just
need
to
sort
of
install
people
on
a
spreadsheet
and
if
we
start
getting
a
thousand
people
sign
up
and
we're
gonna
have
to
rethink
that
strategy.
But
at
the
moment
I
think
it's
quite
doable.
C
C
A
Of
that
as
well
right,
yes,
good
point
good
point:
I
just
had
a
a
guy
that
I
I
know
in
boston,
who's,
who's,
very
interested
in
the
open
approach.
Guy
called
mike
tarcelli
he's
interested
in
receiving
it,
and
that
was
a
message
that
just
came
through
on
a
social
media
platform.
I
guess
I
should
keep
a
copy
of
that
right.
A
Okay,
I
mean
you'll
be
very
handy
if
that
linked
to
the
to
to
it
yeah
okay,
so
you
can
sign
up
and
put
your
details
on
a
sheet
and
it
goes
straight
into
a
spreadsheet,
yeah,
yeah,
okay-
and
someone
has
to
host
that.
So
this
comes
back
to
someone
need
to
make
it
because
we
don't
have
an
open
source
antibiotics
account.
So
it
has
to
be
linked
to
somebody
yeah.
Okay,
all
right,
good,
that's
a
very
good
point
that
would
probably
sort
us
out
for
gdpr
yeah.
C
A
A
Okay,
I
mean
there's
nothing
out
there,
no
movement
on
a
bunch
of
other
things.
Things
are
impossible,
but
nothing's
been
resolved
here.
So
there's
no
other
substantial
things
that
we
need
to
go
through
for
this
meeting.
Did
anybody
want
to
raise
anything
or
ask
a
question
about
the
status
of
anything.
C
A
Yes
right,
I
think
that
that's
like
that's
a
good
point,
and-
and
this
is
where
we
are
kind
of
asking
the
question
about
whether
anybody
has
on
well.
Actually
I
don't
know,
I
don't
know
we,
it
depends
on
what's
active,
we
are
always
on
the
lookout
for
unpublished,
molecules
that
are
relevant,
but
if
we're
changing
to
that
fuse
compound,
then
it
may
be
that
we
need
to
do
a
better
search
for
things
that
are
already
published.
I
suppose.
D
A
Don't
know
if
we've
recently
done
a
nearest
chemical
space
types
we
did
at
the
start,
which
is
where
you
know.
I
think
we
identified
that
gsk
paper
as
being
the
key
resource
yeah,
but
it
would
be
very
neat
to
be
able
to
find
somebody
who
may
have
something
similar
yeah,
so
we're
still
waiting
on
the
data,
though
those.
A
Yeah
yeah
no,
but
I
think
it's
a
good
point
to
make
that
that
we
we
always
need
to
keep
an
eye
out
on
nearest
chemical
space.
That's
published,
but
also
just
just
something
like
you
know,
making
sure
that
we
disseminate
structures
whenever
we
can
and
that's
one
of
the
reasons
why
I
put
a
structure
in
the
email
is
because
that
can
often
trigger
the
imagination
of
someone
who's.
Reading
who
knows
a
molecule,
that's
similar,
so.
C
A
The
moment
at
least
that's
the
simple
way
of
doing
it
yeah
you
know
I
mean
so
yeah
I
mean
at
the
moment
that's
open.
So
so
yeah
I
mean
a
couple
of
milligrams
or
whatever
is
pretty
straightforward
and
that's
worked
pretty
well.
The
the
source
of
the
molecules
from
you
know,
via
ben
perry,
came
in
from
three
different
sources,
so
yeah
it
was
pretty.
That
was
pretty
easy.
C
A
Yeah,
okay,
now
absolutely
I
mean
I
think
the
logistics
are
very
easy.
The
licensing
is
something
that
the
sgc
has
done
about.
Donation
of
compounds,
there's
a
there's,
a
sort
of
click
wrap
trust
agreement
that
they've
got
for
people
who
want
to
donate
molecules,
at
least
they
have
for
the
chemical
probes
program.
But
but
we
don't
have
that,
but
I'm
pretty
sure
we
can
take
the
license
terms
and
adapt
that
so
it
just
spells
out.
Quite
simply
the
it's
like
an
open
mta.
A
A
creative
conversation
has
nothing
to
say
about
chemical
samples,
and
so
it's
important
that
that's
clarified
about
you
know
what
are
you
committing
to
when
you
give
a
sample
in,
but
the
terms
the
last
term
time
I
looked
at
it
was
a
few
weeks
ago
for
the
sgc
site.
It
actually
absolutely
captures
what
we
want.
C
A
That's
a
good
one
in
terms
of
in
terms
of
doing
that,
search,
though
I
mean
trying
to
find
people
with
similar
molecules,
that's
where
it
gets
interesting
I
mean
ultimately,
one
that
you
want
you
want
to
do
is
just
send
the
cam
drawer
to
as
many
chemists
as
you
can,
and
I
don't
know
how
to
do
that.
We
we
put
it
on
twitter
and
stuff,
but
where
I
don't
know
how
to
reach
people
properly,
and
it's
constantly
an
issue.
Yes,.
C
A
D
A
And
yeah
yeah
yeah,
it's
a
good
one,
and
I
it's
one
of
those
things
where
I
think
the
technical
solution
is
not
actually
that
difficult.
It's
just
that
someone's
got
to
do
it,
yeah,
okay,
no
good,
absolutely
so
yeah.
That
should
be
our
first
thought
if
we
get
any
any
activity
on
a
slightly
different
core
for
sure
yeah,
all
right,
good,
that's
everything
I
had
so
unless
anyone's
got
anything
else,
we
can
reserve
a
longer
meeting
for
next
time.